Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65%
TCRT
Zacks Investment ResearchAugust 16, 2023
Due to a lack of funding needs, Alaunos (TCRT) decides to end its only clinical study. The company will instead focus on its hunTR TCR discovery platform and explore broad strategic alternatives.
Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April
TCRT
GlobeNewsWireMarch 29, 2023
HOUSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that company management will be participating in the following upcoming investor conferences.